{"title":"大剂量维生素B6治疗伴抑郁的迟发性运动障碍","authors":"M. McCoy, A. Schindzielorz, S. Holroyd","doi":"10.33470/2379-9536.1372","DOIUrl":null,"url":null,"abstract":"Tardive dyskinesia (TD) is a movement disorder associated with dopamine receptor blocking medications. Recommended treatments for TD include discontinuing the causative agent, adding vesicular monoamine transporter 2 (VMAT2) inhibitors, or adding vitamin B6. We present a 66-year-old Caucasian male with bipolar I disorder who developed TD while on lithium and quetiapine, having been euthymic on this regimen for three years. He was initially treated with 1200 mg B6 daily, which failed to improve his TD and was associated with a depressive episode. He switched to valbenazine 40 mg daily, which improved his TD and concurrently his mood, but months later, the TD symptoms worsened again. Our case adds to the literature by demonstrating that some patients with TD will not respond to vitamin B6. To our knowledge, ours is the first case suggesting the association of high-dose vitamin B6 with depression. This case also demonstrates that response to valbenazine may not last, and further studies are needed.","PeriodicalId":93035,"journal":{"name":"Marshall journal of medicine","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment of Tardive Dyskinesia with High Dose Vitamin B6 Associated with Depression\",\"authors\":\"M. McCoy, A. Schindzielorz, S. Holroyd\",\"doi\":\"10.33470/2379-9536.1372\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Tardive dyskinesia (TD) is a movement disorder associated with dopamine receptor blocking medications. Recommended treatments for TD include discontinuing the causative agent, adding vesicular monoamine transporter 2 (VMAT2) inhibitors, or adding vitamin B6. We present a 66-year-old Caucasian male with bipolar I disorder who developed TD while on lithium and quetiapine, having been euthymic on this regimen for three years. He was initially treated with 1200 mg B6 daily, which failed to improve his TD and was associated with a depressive episode. He switched to valbenazine 40 mg daily, which improved his TD and concurrently his mood, but months later, the TD symptoms worsened again. Our case adds to the literature by demonstrating that some patients with TD will not respond to vitamin B6. To our knowledge, ours is the first case suggesting the association of high-dose vitamin B6 with depression. This case also demonstrates that response to valbenazine may not last, and further studies are needed.\",\"PeriodicalId\":93035,\"journal\":{\"name\":\"Marshall journal of medicine\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Marshall journal of medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33470/2379-9536.1372\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Marshall journal of medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33470/2379-9536.1372","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Treatment of Tardive Dyskinesia with High Dose Vitamin B6 Associated with Depression
Tardive dyskinesia (TD) is a movement disorder associated with dopamine receptor blocking medications. Recommended treatments for TD include discontinuing the causative agent, adding vesicular monoamine transporter 2 (VMAT2) inhibitors, or adding vitamin B6. We present a 66-year-old Caucasian male with bipolar I disorder who developed TD while on lithium and quetiapine, having been euthymic on this regimen for three years. He was initially treated with 1200 mg B6 daily, which failed to improve his TD and was associated with a depressive episode. He switched to valbenazine 40 mg daily, which improved his TD and concurrently his mood, but months later, the TD symptoms worsened again. Our case adds to the literature by demonstrating that some patients with TD will not respond to vitamin B6. To our knowledge, ours is the first case suggesting the association of high-dose vitamin B6 with depression. This case also demonstrates that response to valbenazine may not last, and further studies are needed.